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in-hospital events were major adverse cardiac events 1.7% (N128/7740), death 0.3%,
clinically driven target-lesion revascularization 0.1% (N11/7740). Definite and probable
stent thrombosis rate according to ARC criteria occurred in 0.1% (N15/7740).
Conclusions: This largest real-world experience with the new Resolute Integrity stent
platform demonstrated a low in-hospital event rate including a low rate of stent
thrombosis. Delivery success was high with the Resolute Integrity stent as the first choice
of stent as well as after delivery failure of another stent type.
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Background: A higher rate of adverse cardiac events is associated with percutaneous
coronary intervention (PCI) of ostial lesions compared with non-ostial disease. Adjunctive
imaging using intravascular ultrasound (IVUS) during PCI may improve outcomes in
patients with ostial disease. We evaluated the long-term outcomes of patients with ostial
lesions who underwent PCI with and without the use of IVUS.
Methods: From 7/2002 to 8/2010, we retrospectively identified 225 patients with 233 de
novo coronary ostial lesions that underwent PCI with (n  82) and without (n  143)
IVUS guidance. Ostial lesions included native aorto-ostial (left or right main coronary
arteries) or major coronary vessel (left anterior descending, left circumflex, and ramus
intermedius arteries) occurring within 3 mm of the coronary ostium. Clinical outcomes
[cardiovascular death, all-cause mortality, myocardial infarction (MI), periprocedural MI,
target vessel revascularization (TVR), or target lesion revascularization (TLR)] were
compared between patients with and without the use of IVUS using univariate and
propensity score adjusted analyses.
Results: The majority of patients presented with acute coronary syndrome (80%) and
were followed for a mean of 4.2  2.5 years. The predominant ostial vessel location in
both groups was the right coronary artery (37%) followed by the left anterior descending
coronary artery (31%). Aorto-ostial lesions (n  109) comprised 47% of lesions (IVUS:
n 38; no IVUS n 71), whereas the remaining lesions (53%) involved major coronary
vessels (IVUS: n  46; no IVUS: n  78). After propensity score adjustment, IVUS use
was associated with lower rates of the composite of cardiovascular death, MI, or TLR
(HR 0.54, 95% CI 0.29-0.99; p  0.04), composite MI or TLR (HR 0.39, 95% CI
0.18-0.83; p 0.01) and MI (HR 0.31, 95% CI 0.11-0.85; p 0.02) compared with no
IVUS. The use of IVUS was also associated with a trend towards a lower rate of TLR
(HR 0.42, 95% CI 0.17-1.02; p  0.06). Stent under expansion was observed in 40% of
patients who underwent post-stenting IVUS.
Conclusions: The use of IVUS during PCI of coronary ostial lesions is associated with
significantly lower rates of adverse cardiac events.
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Background: Percutaneous mitral valve repair (PMVR) was introduced as an alternative to
the standard mitral valve surgery (MVS) for severe mitral regurgitation (MR). However, the
ideal patient population to benefit from this procedure is still controversial. This study aimed
to identify a potential comparator reference for future percutaneous mitral repair procedures
based on patients undergoing mitral valve surgery stratified by risk groups.
Methods: 422 patients undergoing isolated MVS were divided into 3 risk strata as
defined by the Society of Thoracic Surgeons (STS) score as follows: STS 3 (Low;
n350), STS 3 to6(Intermediate; n36) and STS6 (High; n36). The in-hospital
and 30-day clinical outcomes were compared.
Results: The average age trended higher as the STS increased (p0.05). The incidence
of female sex, diabetes mellitus, hypertension and peripheral artery disease trended higher
with an increase in the STS score. (Table) The 30-day mortality and stroke rates in the
low-, intermediate- and high-risk groups were (0.9%, 11.1% and 13.4%; p 0.001 and
0.9%, 8.3% and 5.6%; p 0.05, respectively).
Conclusions: In a tertiary center, isolated MVS are generally performed in patients with
low STS scores. Patients with a STS score 6 are at high risk for mortality and should
be subjected to a PMVR. The STS score should be used as a comparator tool to evaluate
the performance of PMVR for patients with severe MR.
Baseline Characteristics
Variable
STS<3
(n350)
3<STS<6
(n36)
STS>6
(n36) P value
Age (yearsSD) 54.712.2 66.316.3 70.910.5 0.05
Average STS scoreSD 0.80.7 40.8 11.96.7 0.05
Female 180 (51.4%) 28 (77.8%) 32 (88.9%) 0.05
Diabetes Mellitus 140 (40.0%) 23 (63.9%) 26 (72.0%) 0.05
Hypertension 26 (7.4%) 12 (33.3%) 12 (33.3%) 0.05
%Mitral Valve Replacement 69 (19.7%) 21 (58.3%) 24 (66.7%) 0.05
Outcome at 30 days
Variable Observed
Predicted
by STS
score Observed
Predicted
by STS
score Observed
Predicted
by STS
score p
All-cause-
mortality
3 (0.9%) 0.8% 4 (11.1%) 4% 5 (13.4%) 11.6% 0.05
Stroke rate 3 (0.9%) 10.5% 3 (8.3%) 4.1% 2 (5.6%) 3.3% 0.05
Renal-failure 1 (0.3%) 2.1% 3 (8.3%) 10% 7 (19.4%) 17.3% 0.05
Length of
stay (days)
6.47.1 4.73.5 15.511.4 175.8 20.123.4 32.814.5 0.001
Post
Operative
Atrial-
ﬁbrillation
95 (27.1%) 19 (52.8%) 9 (25%) 0.005
Total
Packed RBC
transfused
(ml.SD)
392.3
963.6
1221.4
1239.3
1596.2
1642
0.001
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Background: Real world data of acute coronary syndrome (ACS) patients who received
intraaortic balloon pump (IABP) remains limited. Therefore, we evaluate the character-
istics of ACS patients who received IABP support from a real world ACS registry.
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